NEW YORK (GenomeWeb News) – Genomics-based prostate cancer test developer GenomeDx Biosciences today said that it closed a Series B financing round.

The San Diego-based company declined to disclose the amount raised. Merck Global Health Innovation Fund led the round and was joined by Baird Capital Partners, Aeris Capital, and CD Ventures. The funding will go toward expanding the commercialization of GenomeDx's Decipher prostate cancer test, which predicts the risk of developing the disease independent of a PSA test and other commonly used assessment tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.